Occam’s UK Biotech Practice Accelerates with Placement of CSO at Nucleome
Occam’s traction in the UK biotech market continues to grow with the placement of Steve Harrison, an accomplished global entrepreneurial drug hunter, as CSO of Nucleome Therapeutics, an Oxford spin out and M Ventures/J&J Innovation/Pfizer Ventures/OSE/British Patient Capital investment exploring the dark genome for therapeutic opportunities.
Harrison has three decades of experience in the biotechnology sector, with leadership experience at product-driven research organizations at all stages, from target identification to new drug registration and clinical development in multiple therapeutic areas, including immunotherapeutics, oncology, rare diseases, and pain management.
Prior to Nucleome, Harrison held executive leadership positions at several biotechnology companies in the San Francisco Bay Area, most recently as Chief Scientific Officer of Engine Biosciences. Previous roles include Chief Scientific Officer and Senior Vice President at Relypsa (divested to Galencia for $1.53 billion in 2016).
Occam Global is an executive recruiting and leadership advisory firm with specialties across technological fields including Biotech, TechBio, AI-ML, Cell/Gene Therapy, Diagnostics/Genomics, Medical Devices, Research Tools, Digital Health, Alternative Energy, AgTech, EdTech, Robotics as well as adjacencies within Venture Capital and Private Equity. Occam helps build leadership teams that meet the demands of the rapidly developing, competitive, and challenging industries it serves. Occam Global recruits leading C-Suite executives and board members for the most exciting and innovative clients across the world with a specific focus on the UK, Continental Europe, the US, and Asia.